Abstract
Background: Tuberculosis remains a leading cause of death from infectious disease worldwide, and the limited efficacy of Bacille–Guérin (BCG) vaccination against adult pulmonary tuberculosis highlights the need for improved vaccines. Although mucosal BCG vaccination enhances lung immunity, safety concerns associated with pulmonary delivery of live-attenuated mycobacteria limit its clinical translation.Methods: We developed a prime-and-pull vaccination strategy in which systemic immunity was established by subcutaneous BCG vaccination followed by the induction of local lung immunity through mucosal administration of lipid nanoparticle-formulated multi-antigen mRNA. Immunogenicity, inflammatory responses, safety, and protective efficacy were evaluated in murine models of tuberculosis.Findings: Pulmonary delivery of lipid nanoparticle-formulated mRNA induced antigen-specific polyfunctional T-cell responses in the lung while eliciting minimal inflammatory cell infiltration compared with mucosal BCG vaccination. Following BCG priming, the multi-antigen mRNA boost generated robust local immune responses and was well tolerated. In a murine Mycobacterium tuberculosis challenge model, the prime-and-pull strategy conferred protection comparable to mucosal BCG vaccination while avoiding the safety concerns associated with pulmonary administration of live BCG.Interpretation: These findings demonstrate that mRNA-mediated pulmonary immune boosting following parenteral BCG vaccination is a promising and modular strategy to enhance tuberculosis vaccine efficacy while preserving the established safety profile of systemic BCG vaccination. This approach provides a translational platform for next-generation tuberculosis vaccines.